HLS Financial Statements From 2010 to 2025

Stocks . Canada . 
Stock . HLS Therapeutics
HLS Stock  CAD 5.60  0.01  0.18%   
HLS Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing HLS Therapeutics' valuation are provided below:
Gross Profit
40.8 M
Profit Margin
(0.27)
Market Capitalization
175.8 M
Enterprise Value Revenue
3.0211
Revenue
56.4 M
We have found one hundred twenty available fundamental trends for HLS Therapeutics, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to confirm HLS Therapeutics' regular fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself next year. As of the 27th of October 2025, Market Cap is likely to drop to about 69.4 M. In addition to that, Enterprise Value is likely to drop to about 89.9 M

HLS Therapeutics Total Revenue

55.71 Million

Check HLS Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HLS Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 38.6 M, Interest Expense of 10.3 M or Total Revenue of 55.7 M, as well as many indicators such as Price To Sales Ratio of 1.19, Dividend Yield of 0.0102 or PTB Ratio of 0.73. HLS financial statements analysis is a perfect complement when working with HLS Therapeutics Valuation or Volatility modules.
  
This module can also supplement various HLS Therapeutics Technical models . Check out the analysis of HLS Therapeutics Correlation against competitors.

HLS Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets116.1 M159.9 M162.4 M
Slightly volatile
Short and Long Term Debt Total51.5 M100.8 M104.4 M
Very volatile
Other Current Liabilities31.4 K33 K5.9 M
Very volatile
Total Current Liabilities18.2 M22.5 M21.2 M
Slightly volatile
Total Stockholder Equity65.1 M71.3 M89.2 M
Slightly volatile
Property Plant And Equipment Net947.1 K997 K2.6 M
Slightly volatile
Accounts Payable8.9 M8.7 M8.6 M
Slightly volatile
Non Current Assets Total83 M124.5 M121.9 M
Slightly volatile
Net Receivables11.5 M6.7 M11.3 M
Very volatile
Common Stock Shares Outstanding23.5 M31.8 M24.6 M
Slightly volatile
Liabilities And Stockholders Equity116.1 M159.9 M162.4 M
Slightly volatile
Non Current Liabilities Total69.3 M66 M54.3 M
Slightly volatile
Inventory9.5 M9.1 M4 M
Slightly volatile
Total Liabilities51 M88.6 M73.2 M
Slightly volatile
Property Plant And Equipment Gross3 M3.2 M3.3 M
Slightly volatile
Total Current Assets33.1 M35.4 M40.5 M
Pretty Stable
Intangible Assets171 M122.1 M241.1 M
Slightly volatile
Cash18.2 M17.5 M24.1 M
Very volatile
Short Term Investments133 K138.1 K152.4 K
Slightly volatile
Good Will9.4 M10.9 M9.5 M
Slightly volatile
Common Stock Total Equity310.8 M296 M157.7 M
Slightly volatile
Common Stock178.5 M260.6 M148.5 M
Slightly volatile
Other Liabilities1.2 M1.2 M12.4 M
Slightly volatile
Long Term Debt82.4 M60.7 M120.5 M
Slightly volatile
Capital Surpluse11.4 M15.1 M7.4 M
Slightly volatile
Property Plant Equipment958.4 K997 K661 K
Slightly volatile
Non Current Liabilities Other739.1 K778 K2.7 M
Very volatile
Cash And Equivalents20.9 M18.7 M25.1 M
Slightly volatile
Net Invested Capital191.8 M136.9 M270.6 M
Slightly volatile
Short and Long Term Debt8.6 M4.8 M6.5 M
Slightly volatile
Capital Stock278.2 M260.6 M233.2 M
Slightly volatile
Capital Lease Obligations837.2 K882 K952.7 K
Pretty Stable

HLS Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense10.3 M9.8 M6.2 M
Slightly volatile
Total Revenue55.7 M56.6 M64.1 M
Slightly volatile
Gross Profit24.4 M47.6 M35 M
Slightly volatile
Other Operating Expenses51 M66.1 M56.8 M
Very volatile
Total Operating Expenses67.5 M64.3 M35.7 M
Slightly volatile
Selling General Administrative34.2 M32.6 M12.1 M
Slightly volatile
Selling And Marketing Expenses24 M22.9 M9 M
Slightly volatile
Interest Income212.4 K319 K242.7 K
Pretty Stable
Reconciled Depreciation25 M22.7 M31.3 M
Slightly volatile

HLS Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation13.5 M22.7 M20.1 M
Slightly volatile
Capital Expenditures14.2 K15 K4.5 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.191.51272.6749
Slightly volatile
Dividend Yield0.01020.01740.0081
Slightly volatile
PTB Ratio0.731.20051.4067
Slightly volatile
Days Sales Outstanding43.2648.510760.6415
Pretty Stable
Book Value Per Share1.942.24063.2702
Slightly volatile
Average Payables7.1 M7.5 M6.7 M
Pretty Stable
Capex To Depreciation6.0E-46.0E-40.8356
Slightly volatile
PB Ratio0.731.20051.4067
Slightly volatile
Sales General And Administrative To Revenue0.180.18010.1826
Slightly volatile
Average Inventory296.4 K312 K369.8 K
Slightly volatile
Capex To Revenue2.0E-43.0E-40.0775
Pretty Stable
Cash Per Share0.580.54830.9853
Slightly volatile
Intangibles To Total Assets1.390.76374.9641
Slightly volatile
Current Ratio1.491.57029.0655
Pretty Stable
Receivables Turnover13.147.524120.574
Very volatile
Shareholders Equity Per Share1.942.24063.2702
Slightly volatile
Debt To Equity0.730.93142.3643
Slightly volatile
Capex Per Share4.0E-44.0E-40.1788
Very volatile
Average Receivables7.3 M11.7 M11.9 M
Very volatile
Revenue Per Share1.691.77832.9855
Slightly volatile
Interest Debt Per Share1.552.40373.552
Very volatile
Debt To Assets0.550.41562.1185
Slightly volatile
Graham Number2.95.375.5581
Pretty Stable
Short Term Coverage Ratios1.571.65767.3136
Slightly volatile
Price Book Value Ratio0.731.20051.4067
Slightly volatile
Company Equity Multiplier1.892.24141.6934
Slightly volatile
Long Term Debt To Capitalization0.250.45990.5363
Slightly volatile
Total Debt To Capitalization0.270.48230.5132
Pretty Stable
Debt Equity Ratio0.730.93142.3643
Slightly volatile
Quick Ratio1.111.16848.7212
Pretty Stable
Net Income Per E B T1.361.26141.6789
Slightly volatile
Cash Ratio0.740.77438.051
Pretty Stable
Days Of Sales Outstanding43.2648.510760.6415
Pretty Stable
Price To Book Ratio0.731.20051.4067
Slightly volatile
Fixed Asset Turnover30.5356.789467.6193
Very volatile
Debt Ratio0.550.41562.1185
Slightly volatile
Price Sales Ratio1.191.51272.6749
Slightly volatile
Asset Turnover0.340.35410.9398
Slightly volatile
Gross Profit Margin0.880.84110.704
Slightly volatile
Price Fair Value0.731.20051.4067
Slightly volatile

HLS Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap69.4 M85.6 M154.6 M
Slightly volatile

HLS Fundamental Market Drivers

Forward Price Earnings185.1852
Cash And Short Term Investments17.5 M

About HLS Therapeutics Financial Statements

HLS Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how HLS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue6.6 M6.9 M
Total Revenue56.6 M55.7 M
Cost Of Revenue9 M8.5 M
Stock Based Compensation To Revenue 0.03  0.05 
Sales General And Administrative To Revenue 0.18  0.18 
Revenue Per Share 1.78  1.69 
Ebit Per Revenue(0.14)(0.13)

Pair Trading with HLS Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLS Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLS Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with HLS Stock

  0.74BRK Berkshire Hathaway CDRPairCorr
  0.88ELF-PH E L FinancialPairCorr
  0.85FFH-PH Fairfax Financial Earnings Call This WeekPairCorr
  0.77FFH-PJ Fairfax Financial Earnings Call This WeekPairCorr
The ability to find closely correlated positions to HLS Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLS Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLS Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLS Therapeutics to buy it.
The correlation of HLS Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLS Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLS Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLS Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in HLS Stock

HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.
Balance Sheet
Statement
Details
Profit & Loss
Statement
Details
Cash Flow
Statement
Details
Financial
Indicators
Details
Valuation
Indicators
Details
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY